Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Details New Operational Rules for Conditional Approvals from May
Japan’s Ministry of Health, Labor and Welfare (MHLW) has issued new guidance on how the country’s conditional approval system for pharmaceuticals will be operated under the revised Pharmaceuticals and Medical Devices (PMD) Act, which takes effect in May. In a…
To read the full story
Related Article
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- MHLW Issues 15 Notices Ahead of PMD Act Amendment
March 2, 2026
REGULATORY
- Japan, US Launch Talks on Pharma GMP MRA to Ease Inspection Burden
July 3, 2026
- MHLW Gives Kissei until July 21 to Report on Tavneos
July 3, 2026
- Centrist Reform Alliance Warns US MFN Policy Poses “Real Crisis” for Drug Access
July 3, 2026
- Ishin Urges Govt to Make Healthcare, Drug Innovation Core Growth Strategy
July 3, 2026
- MHLW Seeks Sponsors for 6 High-Need Unapproved, Off-Label Drugs
July 2, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…